logo
episode-header-image
Oct 2024
28m 30s

Snack Slump and Obesity Med Discounts. P...

Barron's
About this episode
Jack weighs in on Frito-Lay’s slowdown and the closing loophole for cheap Ozempic. Also, a top Wall Street strategist says don’t be frozen by election fears. 
Up next
Oct 9
Spooky Agents, Cable’s Second Death, and Stock Picks
Jack dives into persistent AI and a broadband land grab, and talks stock picks with Paulina McPadden from Baillie Gifford. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. 
33m 39s
Oct 2
Buybacks, Bond Doubts, DRAM, and T-Rex
It’s a listener question special. Family welcome. Choo-choo! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. 
28m 35s
Sep 25
Weird Ways to Predict Stock Returns
Award-winning economist Alex Edmans discusses his new book, The Madness of Markets. Plus, a global money manager explains where to find value. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertisi ... Show More
31m 55s
Recommended Episodes
Feb 2019
Stocks for the Next 10 Years
Kraft Heinz plummets on weak earnings and an SEC subpoena. Stamps.com loses an Uncle Sam-sized partner. Wayfair delivers. And Zillow renovates. Analysts Andy Cross, Ron Gross, and Jason Moser discuss those stories and dig into the latest from Boston Beer, Domino’s Pizza, Texas Ro ... Show More
40m 15s
Mar 2023
Prof G Markets: Scott’s NJOY Stake, the JetBlue/Spirit Merger, and WeightWatchers Buys Ozempic Maker
This week on Prof G Markets, Scott gives the inside scoop on his early investment in NJOY, which will reap 30x in returns after Altria's acquisition of the vape company goes through. He also shares his thoughts on whether or not the JetBlue/Spirit Merger should be blocked, and ta ... Show More
45m 39s
Nov 2025
Different Reads On The Consumer… And Pharma’s Obesity Drug Price Negotiations 11/5/25
<p>Earnings are filtering in, and companies are seeing a tale of two very different consumers. The group raising concerns about their customer base, and the names not seeing any slowdown. Plus Novo and Eli Lilly nearing a deal with the White house to lower obesity drug prices. Wh ... Show More
43m 47s
Nov 2015
Hot IPOs, Cold Pizza & Star Wars
Wal-Mart surprises. Jack in the Box pops. Square makes its public markets debut. And Urban Outfitters buys a pizza chain? Our analysts discuss those stories and share three stocks on their radar. Plus, corporate governance expert and film critic Nell Minow talks Wall Street refor ... Show More
39m 9s
Feb 2025
Walmart, Etsy Face Tighter Wallets
The key in retail right now? Multiple business segments that can carry companies through reduced discretionary spending. (00:21) Asit Sharma and Jason Moser discuss: - Walmart’s approach to tariffs, and what their results – paired with earnings from Etsy – say about the state ... Show More
41m 31s
Feb 2022
Sell the Rip, Don’t Buy the Dip – Ep 774
* The stock market is rotating, not crashing. * Weak economic data will make it harder for the Fed to tighten. * Fed may begin blaming rising oil prices on economic slowdown. * Market will assign premium to companies producing earnings and paying dividends. * Facebook abandons th ... Show More
43m 46s
Apr 2021
Netflix Earnings and Oscars Preview
Netflix slides on slowing growth. Boston Beer, Chipotle, and Intuitive Surgical serve up big earnings. MarketAxess slips. Johnson & Johnson reports surprising results but continues to deal with vaccine issues. And automation software maker UiPath has a big debut on Wall Street. M ... Show More
39m 10s
Dec 2019
Earnings, Eggnog, and Year-End Financial Advice
Nike scores with its Jordan brand. IAC buys Care.com for $500 million. FedEx delivers disappointing earnings. Bed Bath & Beyond surges after its new CEO cleans house. And General Mills gets a big boost from Blue Buffalo. Motley Fool analysts Ron Gross and Jason Moser discuss thos ... Show More
40m 26s
Nov 2023
The $100 billion opportunity: How anti-obesity drugs are reshaping healthcare and consumer behavior
Goldman Sachs Research’s Chris Shibutani and Jason English explain the business and investor implications of the latest anti-obesity medications and their ripple effects in the healthcare industry and beyond. Learn more about your ad choices. Visit megaphone.fm/adchoices 
26m 30s